Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial

The objective of the GEMINI Phase 3 trial was to evaluate the efficacy and safety of AXS-05 as compared to placebo in patients with moderate or severe MDD.


Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) for the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Randomized, Double-blind, Active-and Placebo-controlled Study

The objective of this study was to evaluate the efficacy and safety of a single dose of AXS-07 compared to its individual components, MoSEIC™ meloxicam and rizatriptan, as well as placebo, for the treatment of a moderate or severe migraine attack in patients with a history of inadequate response to prior acute treatments.


A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Dose of JORNAY PM® (Delayed-Release and Extended-Release Methylphenidate) in a Pivotal Phase 3 Trial

The objective of this post hoc analysis was to determine dose conversion ratios by comparing the dose of prior ADHD medications to the optimized dose of DR/ER-MPH in a pivotal phase 3, laboratory classroom study of children with ADHD.